Which is more effective for weight loss, Wegovy or Mounjaro?

When comparing Wegovy and Mounjaro for weight loss, both medications have shown effectiveness in clinical trials. Wegovy, also known as semaglutide, is a GLP-1 receptor agonist that has been approved by the FDA for chronic weight management. Studies highlight its ability to reduce appetite and food intake, leading to significant weight loss. On the other hand, Mounjaro (tirzepatide) works through a dual mechanism of action as a GIP/GLP-1 receptor agonist and has also demonstrated substantial weight loss in clinical studies. While direct head-to-head comparisons are limited as of the current knowledge, individuals may respond differently to each medication based on their unique health profile. Thus, the decision on which medication is more effective should be tailored to the individual's specific medical history and taken under the guidance of a healthcare professional.